Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs

This training represents regulatory intelligence that sets global standards for clinical research. The content reflects current FDA thinking, emerging guidance, and real-world regulatory experience, providing participants with the most reliable and up-to-date information available.

A newsletter on regulatory science for CDER’s stakeholders

Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet

GE HealthCare issues updated use instructions for certain Carestation 600 and 700 series Anesthesia Systems

CDER’s Office of Pharmaceutical Quality created the Emerging Technology Program to promote the adoption of innovative approaches to pharmaceutical product design and manufacturing.

Unapproved New Drugs/Misbranded Botox